An investigator initiated prospective single arm open-label study to evaluate effectiveness of Camylofin 50 mg and Paracetamol 325mg inpatients with acute colicky abdominal pain - ACAP Study

Start Date10 Feb 2024

Sponsor / Collaborator

Abbott Healthcare Pvt Ltd.

CTRI/2023/04/051566 / Active, not recruitingNot Applicable

Effect of an oral nutrition supplement on growth in Indian children in age group 3-6.9 years at nutritional risk: A prospective, randomized, open label, controlled, parallel study.

Start Date23 Jun 2023

Sponsor / Collaborator

Abbott Healthcare Pvt Ltd.

CTRI/2022/10/046453 / RecruitingPhase 4

A Multicentric Active Post Marketing Surveillance Study to Evaluate the Safety and Tolerability of Vildagliptin 100mg SR formulation in Type 2 Diabetes Mellitus (T2DM) patients - NA

Start Date24 Oct 2022

Sponsor / Collaborator

Abbott Healthcare Pvt Ltd.

100 Clinical Results associated with Abbott Healthcare Pvt Ltd.

0 Patents (Medical) associated with Abbott Healthcare Pvt Ltd.

Literatures (Medical) associated with Abbott Healthcare Pvt Ltd.

01 Feb 2024·AsiaIntervention

Variability in research culture across busy catheterisation labs in the Asia-Pacific region

Article

Author: Saxena, Aseem ; Gopa, Hanumanthu Reddy ; West, Nick E J ; Kaur, Ramneek ; Narang, Manish

BackgroundInformation related to research culture in the busy catheterisation (cath) labs across the Asia-Pacific (APAC) region is sparse.AimsThe aims of this study were to examine the variability in research culture in busy cath labs in the APAC region and to propose a roadmap for hospitals to develop in-house research capabilities in conjunction with industry and academia.MethodsData related to research practices in the APAC region were collected from busy cath labs (at least 250 angioplasty/year) and analysed. Results were shared with research experts to understand the challenges in institutional research and create a roadmap for hospitals to develop research capabilities.ResultsA total of 220 respondents from 62 cath labs (88.6%) across 13 APAC countries participated in the survey. A wide variation was noted in research culture across APAC countries. Well-established infrastructure was reported in Australia, New Zealand, South Korea, Singapore, and Japan. Large multicentre trials were common in South Korea, while routine follow-ups were common in Japan. Linking medical records across hospitals/states was considered challenging. Research exposure and training were limited in the APAC region. The experts suggested a roadmap, including creating a conducive regulatory environment, forming synergistic goals, training programs for the professionals involved in research, and leveraging best practices, for improving the research culture in APAC.ConclusionsClinical research in cardiology has grown significantly in the APAC region, with a huge research potential in China and India. Implementing measures to improve research training and involvement of the industry will boost the research culture in the APAC region.

01 Dec 2023·Indian Journal of Otolaryngology and Head & Neck Surgery

Effectiveness and Safety of Prochlorperazine in Indian Patients with Acute Vertigo: Results from a Large, Prospective, Post-marketing Observational Study

Article

Author: Kameswaran, Mohan ; Chandra, Sudipta ; Reddy, Hari Krishna ; Bharathi, M B ; Sholapuri, Deepa ; Peethamabaran, Kartik ; Gupta, Manjeeta ; Periera, Carlton

AbstractAimTo assess the efficacy and safety of prochlorperazine in Indian patients with acute vertigo.MethodsIn this prospective, multicenter, open-label, post-marketing observational study, patients with acute peripheral vertigo of different etiologies received 5 mg prochlorperazine thrice a day for 5 days. The primary endpoints were percentage of patients with improvement in (1) vertigo symptoms and (2) clinical response as per scale for vestibular vertigo severity level and clinical response evaluation (SVVSLCRE) from baseline to end of treatment (Day 6). The key secondary endpoints were (1) improvement in nystagmus grading, and (2) safety and tolerability Efficacy of prochlorperazine by route of administration of first prochlorperazine dose (oral or intramuscular) was also assessed.ResultsOf 1716 enrolled patients (mean [standard deviation, SD]) age (42.0 [12.95] years; 53.6% men), 57.4% were diagnosed with Meniere’s disease, followed by vestibular neuritis (17.4%), labyrinthitis (16.7%), or ear surgery (8.5%). In the overall population, 91.1% of patients showed improvement in clinical response per SVVSLCRE grading at Day 6 (p < 0.0001 vs. non-responders). Nystagmus grading was improved in 99.7% (of patients. No adverse drug reactions events were reported. Tolerability of prochlorperazine was rated as good, very good, and excellent by 43.6%, 32.9% and 20.7% of patients, respectively. Among patients with postoperative vertigo, 80.1% showed improvement in clinical response. In the intramuscular and oral subsets, 85.5% and 92.1% of patients showed improved clinical response, respectively.ConclusionProchlorperazine showed improvement in severity of symptoms and clinical response in all subsets of vertigo patients, with a good safety and tolerability profile.Trial Registration NumberCTRI/2022/01/039287.Date of Registration10 January 2022.

01 Apr 2023·International Journal of Epilepsy

Brivaracetam in the Management of Focal Epilepsy in Indian Clinical Practice: Results of a Physician Survey

Author: Upendra, Greeshma ; Gupta, Praveen

100 Deals associated with Abbott Healthcare Pvt Ltd.

100 Translational Medicine associated with Abbott Healthcare Pvt Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 20 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Abbott Healthcare Pvt Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 20 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing